Status:

COMPLETED

PBMT for the Prevention of CIPN

Lead Sponsor:

Hasselt University

Collaborating Sponsors:

Jessa Hospital

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

ne of the most common cancers in women worldwide is breast cancer. A common used therapy in early-stage and metastatic breast cancer involves chemotherapy. Taxanes, microtubule-targeting agents (MTAs)...

Eligibility Criteria

Inclusion

  • Diagnosed with non-invasive (stage 0) or invasive (stage 1, 2 and 3A) breast adenocarcinoma
  • Age 18 years or above
  • Are planned to undergo at least 3 cycles of taxane treatment (i.e. paclitaxel or docetaxel)
  • Have no documented or observable psychiatric or neurological disorders that might interfere with study participation (e.g., dementia or psychosis).
  • Signed informed consent

Exclusion

  • Have a history of neuropathy before taxane treatment due to other medical conditions: diabetes, peripheral vascular disease, HIV infection, significant degenerative or familial neurologic disorder, nerve compression injuries (i.e., carpal tunnel syndrome, brachial plexopathy, spinal stenosis, or spinal nerve root compression)
  • Taking stable doses of medication on prescription or dietary supplements for peripheral neuropathy. Related medications are: gabapentin, pregabalin, nortriptyline, amitriptyline, duloxetine, venlafaxine; lidocaine, opioid tramadol and other narcotics; NSAIDs; glutamine, glutathione, vitamin E and vitamin B12; Patients need to agree not to initiate a new therapy two weeks before and during the study period.
  • Metastatic disease
  • Have a diagnosis of ethanol addiction or dependence within the past 10 years.
  • Concurrent chemotherapy with neurotoxic chemotherapeutic agents (i.e. platinum compounds or vinca alcaloids)
  • Severe or unstable cardio- respiratory or musculoskeletal disease

Key Trial Info

Start Date :

November 13 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 22 2021

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT03391271

Start Date

November 13 2017

End Date

June 22 2021

Last Update

September 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Jessa Ziekenhuis

Hasselt, Belgium, 3500

PBMT for the Prevention of CIPN | DecenTrialz